SMAD3 and Alzheimer disease: On the other hand, the TGF-β signaling pathway is underregulated during AD, where SMAD2, SMAD3, and SMAD4, signal transducers in the pathway, have been decreased in the temporal cortex of patients with this disease (Ueberham et al., 2012).